Drug Discovery

Cyclic Peptide Inhibitors of KRAS

Challenges and Advantages in the Development of Cyclic Peptide Inhibitors of KRAS

Over the past several decades, direct inhibition of the RAS family of oncogenic proteins has been a significant challenge in the field of drug development. Despite accounting for approximately 30% […]

antibody drug conjugate

ADC Cleavable Linker: Classification and Mechanism of Action

Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances […]

siRNA Design

Optimization of siRNA Design

The length of siRNA is 7-8 nm, the diameter is 2-3 nm, the molecular weight is 13-14 kDa, and it is hydrophilic. Therefore, unmodified and naked siRNA cannot passively cross […]

ADC targets

Nectin-4: A New Target of ADC

Overview of Nectin Nectin, a cell adhesion molecule belonging to the Immunoglobulin (Ig) superfamily, is a homologue of poliovirus receptor (PVR/CD155). It also known as poliovirus receptor-associated protein Receptor Related Protein (PVRL). […]

Peptide-drug Conjugate

Overview of Peptide-drug Conjugate

The concept of drug conjugates originated in the early 20th century. In 1910, Paul Ehrlich proposed the “Magic Bullet” theory, which aimed to describe the concept of a drug that […]

antibody drug conjugate

FDA Approved Antibody-Drug Conjugates (ADCs) By 2023

Antibody Drug Conjugate (ADC) is a complex formed by linking cytotoxic drugs to tumor-targeting monoclonal antibodies. It combines the characteristics of targeted drugs and chemotherapy drugs to achieve precise treatment. The concept […]

Telomere Targeting Chimera

Literature Interpretation (JACS): Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins

Today I would like to share with you an article published in JACS titled “Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins”. This article developed a nucleotide-based […]

drug discovery

Research Progress of Small Molecule Drugs Targeting PD-1/PD-L1

Immunotherapy, which uses immune pathways to treat cancer, is rapidly becoming an accepted cancer treatment after surgery, chemotherapy and radiation. Checkpoint blocking using monoclonal antibodies against cytotoxic T lymphocyte-associated protein […]

drug discovery

Advances in Research on Small Molecule Janus Kinase (JAK) Inhibitors

Janus kinases (JAKs) belong to the non-receptor tyrosine kinase family, and their JAK-STAT signaling pathway with signal transducers and activators of transcription (STAT) can affect cell proliferation, differentiation, apoptosis, and […]

lab experiment

FDA-approved small molecule kinase inhibitors-Part 3

Fostamatinib is the precursor drug of active metabolite R406. It is a Syk inhibitor with an IC50 value of 41 nM. It strongly inhibits Syk but does not inhibit Lyn. […]